Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol.
D000818:Animals; D001794:Blood Pressure; D002395:Catecholamines / Q000378:metabolism; D002415:Cats; D004285:Dogs; D005934:Glucagon / Q000494:pharmacology* / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006325:Heart Atria / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006614:Hindlimb / Q000187:drug effects; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D010210:Papillary Muscles / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology*; D011955:Receptors, Drug; D012110:Reserpine / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects
D002395:Catecholamines; D011955:Receptors, Drug; D012110:Reserpine; D005934:Glucagon; D011433:Propranolol